Curated News
By: NewsRamp Editorial Staff
October 10, 2025
Lifordi's LFD-200 ADC Shows Targeted Steroid Delivery Without Toxicity
TLDR
- Lifordi's LFD-200 ADC technology offers a competitive edge by delivering steroid efficacy without systemic toxicity, potentially capturing significant autoimmune treatment market share.
- Lifordi's LFD-200 uses antibody drug conjugate technology to selectively deliver glucocorticoids to immune cells through VISTA targeting, achieving sustained anti-inflammatory effects without systemic toxicity.
- Lifordi's LFD-200 could improve autoimmune patients' quality of life by providing safer, less frequently dosed steroid treatments with reduced side effects.
- Lifordi's innovative antibody drug conjugate delivers steroids directly to immune cells, achieving targeted treatment effects without the typical systemic toxicity concerns.
Impact - Why it Matters
This development represents a potential breakthrough for the millions of patients suffering from autoimmune and inflammatory diseases who currently face limited treatment options with significant side effects. Traditional glucocorticoid treatments, while effective, often cause systemic toxicity that limits long-term use and can lead to serious complications including osteoporosis, diabetes, and increased infection risk. Lifordi's targeted approach could revolutionize autoimmune disease management by providing the anti-inflammatory benefits of steroids without the dangerous side effects, potentially enabling safer long-term treatment and improved quality of life for patients with conditions like rheumatoid arthritis, lupus, and other chronic inflammatory disorders. The successful development of this technology could set a new standard for precision medicine in immunology.
Summary
Lifordi Immunotherapeutics, a pioneering biotech company based in Burlington, MA, is making significant strides in autoimmune treatment with its lead candidate LFD-200. The company will present compelling preclinical data at the American College of Rheumatology (ACR) Convergence 2025 meeting, demonstrating that their antibody drug conjugate achieves targeted delivery of glucocorticoids directly to immune cells without systemic toxicity. These findings from multiple in vitro and in vivo studies in non-human primates show that LFD-200 provides sustained anti-inflammatory effects while maintaining a favorable safety profile at clinically relevant doses, potentially offering patients a safer, less frequently dosed treatment option for autoimmune and inflammatory disorders.
The research presented in the Rheumatoid Arthritis – Treatment Poster I session reveals that LFD-200 selectively delivers its glucocorticoid payload to immune tissues and effectively inhibits ex vivo induced inflammatory cytokines. This targeted approach represents a breakthrough in steroid therapy, as it maintains the efficacy of traditional steroids while eliminating the systemic toxicity that often limits their long-term use. The data will be featured on Sunday, October 26, 2025, during the ACR Convergence 2025 meeting, highlighting Lifordi's innovative approach to treating immune-mediated diseases through advanced antibody drug conjugate technology.
Lifordi's platform extends beyond LFD-200, with applications for diverse payloads including small molecules, antisense oligonucleotides, and siRNA. The company's strong financial backing from ARCH Venture Partners, 5AM Ventures, and Atlas Venture supports their commitment to revolutionizing immune and inflammatory disease treatment. With LFD-200 currently in Phase 1 clinical trials and demonstrating efficacy across multiple preclinical disease models, Lifordi is positioned to transform how autoimmune conditions are managed, offering hope for millions of patients who currently face limited treatment options with significant side effects.
Source Statement
This curated news summary relied on content disributed by Reportable. Read the original source here, Lifordi's LFD-200 ADC Shows Targeted Steroid Delivery Without Toxicity
